237 related articles for article (PubMed ID: 22998153)
1. Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX.
Collins PW; Møss J; Knobe K; Groth A; Colberg T; Watson E
J Thromb Haemost; 2012 Nov; 10(11):2305-12. PubMed ID: 22998153
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of a novel extended half-life glycoPEGylated factor IX, nonacog beta pegol (N9-GP) in previously treated patients with haemophilia B: results from two phase 3 clinical trials.
Tiede A; Abdul-Karim F; Carcao M; Persson P; Clausen WHO; Kearney S; Matsushita T; Negrier C; Oldenburg J; Santagostino E; Young G
Haemophilia; 2017 Jul; 23(4):547-555. PubMed ID: 28233381
[TBL] [Abstract][Full Text] [Related]
3. Measuring factor IX activity of nonacog beta pegol with commercially available one-stage clotting and chromogenic assay kits: a two-center study.
Bowyer AE; Hillarp A; Ezban M; Persson P; Kitchen S
J Thromb Haemost; 2016 Jul; 14(7):1428-35. PubMed ID: 27107268
[TBL] [Abstract][Full Text] [Related]
4. Nonacog beta pegol in previously treated children with hemophilia B: results from an international open-label phase 3 trial.
Carcao M; Zak M; Abdul Karim F; Hanabusa H; Kearney S; Lu MY; Persson P; Rangarajan S; Santagostino E
J Thromb Haemost; 2016 Aug; 14(8):1521-9. PubMed ID: 27174727
[TBL] [Abstract][Full Text] [Related]
5. Once-weekly prophylaxis with 40 IU/kg nonacog beta pegol (N9-GP) achieves trough levels of >15% in patients with haemophilia B: Pooled data from the paradigm™ trials.
Oldenburg J; Carcao M; Lentz SR; Mahlangu J; Mancuso ME; Matsushita T; Négrier C; Clausen WHO; Ehrenforth S; Young G
Haemophilia; 2018 Nov; 24(6):911-920. PubMed ID: 30248217
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and pharmacodynamic properties of plasma-derived vs. recombinant factor IX in patients with hemophilia B: a prospective crossover study.
Alamelu J; Bevan D; Sorensen B; Rangarajan S
J Thromb Haemost; 2014 Dec; 12(12):2044-8. PubMed ID: 25315324
[TBL] [Abstract][Full Text] [Related]
7. Population Pharmacokinetic Modeling Of On-Demand And Surgical Use Of Nonacog Beta Pegol (N9-GP) And rFIXFc Based Upon The paradigm 7 Comparative Pharmacokinetic Study.
Simpson ML; Kulkarni R; Escuriola Ettingshausen C; Medom Meldgaard R; Cooper DL; Klamroth R
J Blood Med; 2019; 10():391-398. PubMed ID: 32009825
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Safety and Efficacy of Nonacog Beta Pegol (N9-GP) Administered for at Least 5 Years in Previously Treated Children with Hemophilia B.
Carcao M; Kearney S; Lu MY; Taki M; Rubens D; Shen C; Santagostino E
Thromb Haemost; 2020 May; 120(5):737-746. PubMed ID: 32369845
[TBL] [Abstract][Full Text] [Related]
9. Qualification of a select one-stage activated partial thromboplastin time-based clotting assay and two chromogenic assays for the post-administration monitoring of nonacog beta pegol.
Tiefenbacher S; Bohra R; Amiral J; Bowyer A; Kitchen S; Lochu A; Rosén S; Ezban M
J Thromb Haemost; 2017 Oct; 15(10):1901-1912. PubMed ID: 28772338
[TBL] [Abstract][Full Text] [Related]
10. Prophylactic administration of glycoPEGylated factor IX provides protection and joint outcome superior to recombinant factor IX after induced joint bleeding.
Sun J; Livingston EW; Broberg ML; Johansen PB; Ley CD; Knudsen T; Ezban M; Bateman T; Monahan PE; Taves S
J Thromb Haemost; 2019 Aug; 17(8):1240-1246. PubMed ID: 31148392
[TBL] [Abstract][Full Text] [Related]
11. GlycoPEGylated recombinant factor IX for hemophilia B in context.
Santagostino E; Mancuso ME
Drug Des Devel Ther; 2018; 12():2933-2943. PubMed ID: 30254423
[TBL] [Abstract][Full Text] [Related]
12. In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates.
Preijers T; Bukkems L; van Spengler M; Leebeek F; Cnossen M; Mathôt R
Eur J Clin Pharmacol; 2021 Aug; 77(8):1193-1200. PubMed ID: 33624121
[TBL] [Abstract][Full Text] [Related]
13. Nonacog beta pegol (N9-GP) in haemophilia B: A multinational phase III safety and efficacy extension trial (paradigm™4).
Young G; Collins PW; Colberg T; Chuansumrit A; Hanabusa H; Lentz SR; Mahlangu J; Mauser-Bunschoten EP; Négrier C; Oldenburg J; Patiroglu T; Santagostino E; Tehranchi R; Zak M; Karim FA
Thromb Res; 2016 May; 141():69-76. PubMed ID: 26970716
[TBL] [Abstract][Full Text] [Related]
14. Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B.
Negrier C; Knobe K; Tiede A; Giangrande P; Møss J
Blood; 2011 Sep; 118(10):2695-701. PubMed ID: 21555744
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics, tissue distribution, excretion, and metabolite profiling of PEGylated rFIX (nonacog beta pegol, N9-GP) in rats.
Sternebring O; Christensen JK; Bjørnsdottir I
Eur J Pharm Sci; 2016 Sep; 92():163-72. PubMed ID: 27378188
[TBL] [Abstract][Full Text] [Related]
16. FIXing postinfusion monitoring: Assay experiences with N9-GP (nonacog beta pegol; Refixia
Ezban M; Hermit MB; Persson E
Haemophilia; 2019 Jan; 25(1):154-161. PubMed ID: 30664825
[TBL] [Abstract][Full Text] [Related]
17. Recombinant long-acting glycoPEGylated factor IX (nonacog beta pegol) in haemophilia B: assessment of target joints in multinational phase 3 clinical trials.
Negrier C; Young G; Abdul Karim F; Collins PW; Hanabusa H; Colberg T; Goldman B; Walsh CE;
Haemophilia; 2016 Jul; 22(4):507-13. PubMed ID: 26936227
[TBL] [Abstract][Full Text] [Related]
18. Overestimation of N-glycoPEGylated factor IX activity in a one-stage factor IX clotting assay owing to silica-mediated premature conversion to activated factor IX.
Rosén P; Rosén S; Ezban M; Persson E
J Thromb Haemost; 2016 Jul; 14(7):1420-7. PubMed ID: 27169618
[TBL] [Abstract][Full Text] [Related]
19. Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide.
Østergaard H; Bjelke JR; Hansen L; Petersen LC; Pedersen AA; Elm T; Møller F; Hermit MB; Holm PK; Krogh TN; Petersen JM; Ezban M; Sørensen BB; Andersen MD; Agersø H; Ahmadian H; Balling KW; Christiansen ML; Knobe K; Nichols TC; Bjørn SE; Tranholm M
Blood; 2011 Aug; 118(8):2333-41. PubMed ID: 21700771
[TBL] [Abstract][Full Text] [Related]
20. A commentary on the differences in pharmacokinetics between recombinant and plasma-derived factor IX and their implications for dosing.
Björkman S
Haemophilia; 2011 Mar; 17(2):179-84. PubMed ID: 21299739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]